APOE risk variants exhibited worse cognitive screening, reduced executive functioning, and significantly more severe apathy compared S-FTD (GR3) patients, but fewer scores of current neuropsychiatric symptoms than GR1 patients (Fig. 1E and Tables 1 and 2). The gene discussed is APOE; the disease is frontotemporal dementia.